Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2018
A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer
Epistemonikos ID: 5039787af468982e2a9915e16cea5aef716efbf7
First added on: May 21, 2024